Get started
Author

Fabienne Calvas

Observed names: F Calvas, F. Calvas
Observed institutions: Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Innsbruck Medical University, Inserm, Universität Innsbruck, Aix-Marseille Université, Centre Hospitalier Universitaire de Toulouse, Sorbonne Université, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire Amiens-Picardie, Institut de Neurosciences des Systèmes, Universitätsmedizin Göttingen, Paracelsus Elena Klinik Kassel, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Hôpital Purpan, Hôpitaux Universitaires de Strasbourg, Institut du Cerveau, Hôpital d'Hautepierre, Hôpital de la Timone, Centre d’Investigation Clinique 1436, Toulouse NeuroImaging Center, Université Pierre-et-Marie-Curie, University of Göttingen, Institut Curie
OpenAlex ID: A5081833243
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
2018 · Ralf Reilmann, Andrew McGarry, et al. · The Lancet Neurology · 111
Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
2010 · Estelle Dellapina, Angélique Gerdelat‐Mas, et al. · Movement Disorders · 94
Mismatch Profile Influences Outcome After Mechanical Thrombectomy
2020 · Jean-Marc Olivot, Jean-François Albucher, et al. · Stroke · 85
Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic‐euglycaemic clamp
2017 · Pierre Gourdy, Laurent Cazals, et al. · Diabetes Obesity and Metabolism · 66
Added value of 18 F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study
2017 · Mathieu Ceccaldi, Mathieu Ceccaldi, et al. · Alzheimer s & Dementia · 56
PDF
Clinical manifestations of intermediate allele carriers in Huntington disease
2016 · Esther Cubo, María A. Ramos-Arroyo, et al. · Neurology · 52
A randomized, double‐blind, placebo‐controlled trial evaluating cysteamine in Huntington's disease
2017 · Christophe Verny, Anne‐Catherine Bachoud‐Lévi, et al. · Movement Disorders · 45
Diabetes Mellitus and Cognition
2021 · Eric Frison, Cecile Proust-Lima, et al. · Neurology · 42
PDF
Neural substrates of low‐frequency repetitive transcranial magnetic stimulation during movement in healthy subjects and acute stroke patients. A PET study
2008 · Fabrice Conchou, Isabelle Loubinoux, et al. · Human Brain Mapping · 39
PDF
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers
2025 · Vincent Bouteloup, Nicolas Villain, et al. · JAMA Neurology · 38
PDF
Reduced Cancer Incidence in Huntington’s Disease: Analysis in the Registry Study
2018 · Paul McNulty, Richard Pilcher, et al. · Journal of Huntington s Disease · 35
Low cancer prevalence in polyglutamine expansion diseases
2017 · Giulia Coarelli, Alhassane Diallo, et al. · Neurology · 34
Quantification of Penumbral Volume in Association With Time From Stroke Onset in Acute Ischemic Stroke With Large Vessel Occlusion
2023 · Pierre Seners, Nicole Yuen, et al. · JAMA Neurology · 25
Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
2025 · Kirsten I. Taylor, Florian Lipsmeier, et al. · npj Digital Medicine · 17
PDF
Both L-DOPA and HFS-STN restore the enhanced group II spinal reflex excitation to a normal level in patients with Parkinson’s disease
2010 · V. Marchand-Pauvert, A. Gerdelat-Mas, et al. · Clinical Neurophysiology · 15
Location-weighted versus Volume-weighted Mismatch at MRI for Response to Mechanical Thrombectomy in Acute Stroke
2022 · Hikaru Fukutomi, Takayuki Yamamoto, et al. · Radiology · 14
PDF
Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)
2017 · Célia Lloret-Linares, Youssef Daali, et al. · BMC Pharmacology and Toxicology · 8
PDF
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France
2026 · Lisa Le Scouarnec, Vincent Bouteloup, et al. · The Journal of Prevention of Alzheimer s Disease
Estimating the prevalence of amyloid positivity among older adults without dementia in the general population
2026 · Lisa Le Scouarnec, Vincent Bouteloup, et al. · npj Dementia
PDF
PatientSpace: A multimodal graph-based latent representation framework for modeling neurodegenerative disease heterogeneity
2026 · Dorian Manouvriez, Grégory Kuchcinski, et al. · NeuroImage
PDF
Methodological approaches to account for assay changes in longitudinal biomarker analysis: insights from Alzheimer’s blood biomarkers in the MEMENTO cohort
2026 · Vincent Bouteloup, Cécile Proust-Lima, et al. · Alzheimer s Research & Therapy
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials
2025 · Gennaro Pagano, Dylan Trundell, et al. · npj Parkinson s Disease
PDF
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials (npj Parkinson's Disease, (2025), 11, 1, (193), 10.1038/s41531-025-01041-9)
2025 · Gennaro Pagano, Dylan Trundell, et al. · Newcastle University ePrints (Newcastle Univesity)
Traitement de la maladie d’Alzheimer : une lueur au bout du tunnel ?
2019 · J. Pariente, M. Rafiq, et al. · Pratique Neurologique - FMC
M2 A randomised, double-blind, placebo-controlled trial evaluating cysteamine in huntington’s disease
2016 · Dominique Bonneau, Anne-Catherine Bachoud-Lévi, et al. · Journal of Neurology Neurosurgery & Psychiatry
Works count: 27
Citation count: 776
H-index: 15
I10-index: 16
Year
Topic
Type